- |||||||||| PF-06412562 / Pfizer, Cerevel Therap
Trial completion, Trial completion date, Trial primary completion date, Metastases: PF 06412562 in Subjects With Advanced Stage Parkinson's Disease (clinicaltrials.gov) - Jul 30, 2019
P1, N=8, Completed,
No abstract available Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Apr 2019 | Trial primary completion date: Dec 2019 --> Mar 2019
- |||||||||| carbidopa/levodopa / Generic mfg.
Enrollment open: ESTREL: Enhancement of Stroke Rehabilitation With Levodopa (clinicaltrials.gov) - Jun 17, 2019
P3, N=610, Recruiting,
Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Apr 2019 | Trial primary completion date: Dec 2019 --> Mar 2019 Not yet recruiting --> Recruiting
- |||||||||| carbidopa/levodopa / Generic mfg., levodopa/carbidopa orally disintegrating tablets / Generic mfg.
Enrollment change, Trial termination: Vision Response to Dopamine Replacement (clinicaltrials.gov) - Jun 12, 2019
P2, N=20, Terminated,
Not yet recruiting --> Recruiting N=50 --> 20 | Recruiting --> Terminated; Lack of funding
- |||||||||| carbidopa/levodopa / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome (clinicaltrials.gov) - Apr 22, 2019
P=N/A, N=10, Completed,
No abstract available Enrolling by invitation --> Completed | N=15 --> 10 | Trial completion date: Nov 2019 --> Feb 2019 | Trial primary completion date: Nov 2018 --> Feb 2019
- |||||||||| PF-06412562 / Pfizer, Cerevel Therap
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: PF 06412562 in Subjects With Advanced Stage Parkinson's Disease (clinicaltrials.gov) - Apr 18, 2019
P1, N=8, Active, not recruiting,
Enrolling by invitation --> Completed | N=15 --> 10 | Trial completion date: Nov 2019 --> Feb 2019 | Trial primary completion date: Nov 2018 --> Feb 2019 Recruiting --> Active, not recruiting | Trial completion date: Mar 2019 --> Dec 2019 | Trial primary completion date: Mar 2019 --> Dec 2019
- |||||||||| carbidopa/levodopa / Generic mfg.
Trial completion date, Trial primary completion date: Dose Ranging Study of Carbidopa-levodopa (clinicaltrials.gov) - Apr 7, 2019
P2, N=52, Recruiting,
Recruiting --> Active, not recruiting | Trial completion date: Mar 2019 --> Dec 2019 | Trial primary completion date: Mar 2019 --> Dec 2019 Trial completion date: Feb 2019 --> Feb 2021 | Trial primary completion date: Dec 2018 --> Dec 2020
- |||||||||| carbidopa/levodopa / Generic mfg.
Trial completion date, Trial primary completion date: Carbidopa-levodopa in Neovascular AMD (clinicaltrials.gov) - Apr 7, 2019
P2, N=52, Recruiting,
Trial completion date: Feb 2019 --> Feb 2021 | Trial primary completion date: Dec 2018 --> Dec 2020 Trial completion date: Feb 2019 --> Feb 2020 | Trial primary completion date: Dec 2018 --> Dec 2019
- |||||||||| carbidopa/levodopa / Generic mfg.
Trial completion date, Trial primary completion date: Extension, Carbidopa-levodopa in Neovascular AMD (clinicaltrials.gov) - Apr 5, 2019
P2, N=52, Recruiting,
Trial completion date: Feb 2019 --> Feb 2020 | Trial primary completion date: Dec 2018 --> Dec 2019 Trial completion date: Mar 2019 --> Mar 2021 | Trial primary completion date: Dec 2018 --> Dec 2020
- |||||||||| Biomarker, Trial completion date, Trial primary completion date: Measuring Parkinson's Disease Progression (clinicaltrials.gov) - Mar 26, 2019
P1, N=40, Recruiting,
N=104 --> 0 | Suspended --> Withdrawn Trial completion date: Feb 2019 --> Sep 2019 | Trial primary completion date: Feb 2019 --> Sep 2019
- |||||||||| PF-06412562 / Pfizer, Cerevel Therap
Trial completion date, Trial primary completion date, Metastases: PF 06412562 in Subjects With Advanced Stage Parkinson's Disease (clinicaltrials.gov) - Feb 18, 2019
P1, N=8, Recruiting,
Trial completion date: Feb 2019 --> Sep 2019 | Trial primary completion date: Feb 2019 --> Sep 2019 Trial completion date: Dec 2018 --> Mar 2019 | Trial primary completion date: Dec 2018 --> Mar 2019
- |||||||||| carbidopa/levodopa / Generic mfg.
Enrollment open, Phase classification: L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults (clinicaltrials.gov) - Jan 17, 2019
P4, N=90, Recruiting,
Trial completion date: Dec 2018 --> Mar 2019 | Trial primary completion date: Dec 2018 --> Mar 2019 Not yet recruiting --> Recruiting | Phase classification: PN/A --> P4
- |||||||||| Trial primary completion date: Gait Analysis in Neurological Disease (clinicaltrials.gov) - Dec 12, 2018
P=N/A, N=110, Recruiting,
Not yet recruiting --> Recruiting | Phase classification: PN/A --> P4 Trial primary completion date: Oct 2018 --> Oct 2019
- |||||||||| carbidopa/levodopa / Generic mfg.
Enrollment open, Trial initiation date: Carbidopa-Levodopa in Dry AMD With Geographic Atrophy (clinicaltrials.gov) - Sep 6, 2018
P2, N=254, Recruiting,
Trial primary completion date: Oct 2018 --> Oct 2019 Not yet recruiting --> Recruiting | Initiation date: Apr 2018 --> Jul 2018
- |||||||||| Enrollment change: Gait Analysis in Neurological Disease (clinicaltrials.gov) - Dec 14, 2017
P=N/A, N=100, Recruiting,
Not yet recruiting --> Completed | N=78 --> 150 N=60 --> 100
- |||||||||| Biomarker, Phase classification, Trial initiation date: Measuring Parkinson's Disease Progression (clinicaltrials.gov) - Nov 6, 2017
P1, N=40, Recruiting,
N=60 --> 100 Phase classification: P=N/A --> P1 | Initiation date: Jul 2017 --> Oct 2017
- |||||||||| carbidopa/levodopa / Generic mfg.
Enrollment open: Extension, Carbidopa-levodopa in Neovascular AMD (clinicaltrials.gov) - Oct 23, 2017
P2, N=52, Recruiting,
Phase classification: P=N/A --> P1 | Initiation date: Jul 2017 --> Oct 2017 Not yet recruiting --> Recruiting
- |||||||||| carbidopa/levodopa / Generic mfg.
Trial primary completion date: Dose Ranging Study of Carbidopa-levodopa (clinicaltrials.gov) - Oct 23, 2017
P2, N=52, Recruiting,
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2017 --> Dec 2018
- |||||||||| carbidopa/levodopa / Generic mfg.
Trial primary completion date: Carbidopa-levodopa in Neovascular AMD (clinicaltrials.gov) - Oct 23, 2017
P2, N=52, Recruiting,
Trial primary completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Dec 2017 --> Dec 2018
- |||||||||| carbidopa/levodopa / Generic mfg., naproxen ER / Generic mfg., naproxen / Generic mfg.
Trial completion, Trial primary completion date: Effect of L-dopa In Subacute Back Pain Population (clinicaltrials.gov) - Oct 11, 2017
P4, N=125, Completed,
Recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Sep 2017
- |||||||||| carbidopa/levodopa / Generic mfg., levodopa/carbidopa orally disintegrating tablets / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Striatal Effective Connectivity to Predict Treatment Response in Cocaine Misuse (clinicaltrials.gov) - Sep 27, 2017
P2, N=131, Completed,
Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Sep 2017 Recruiting --> Completed | N=90 --> 131 | Trial primary completion date: Aug 2017 --> Jan 2017
- |||||||||| ODM-104 / Orion Corp
Trial completion: Pharmacokinetic of Levodopa Study in Healthy Males (clinicaltrials.gov) - Sep 26, 2017
P1, N=20, Completed,
Recruiting --> Completed | N=90 --> 131 | Trial primary completion date: Aug 2017 --> Jan 2017 Active, not recruiting --> Completed
- |||||||||| citalopram / Generic mfg., carbidopa/levodopa / Generic mfg.
Trial primary completion date: SELEIS: Effect of Serotonin and Levodopa in Ischemic Stroke (clinicaltrials.gov) - Aug 14, 2017
P4, N=240, Recruiting,
Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Mar 2017
- |||||||||| ODM-104 / Orion Corp
Enrollment closed: Pharmacokinetic of Levodopa Study in Healthy Males (clinicaltrials.gov) - Jul 31, 2017
P1, N=20, Active, not recruiting,
Trial primary completion date: Dec 2016 --> Mar 2017 Recruiting --> Active, not recruiting
- |||||||||| carbidopa/levodopa / Generic mfg.
Biomarker, Trial initiation date, Trial suspension, Trial primary completion date, Metastases: A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration (clinicaltrials.gov) - May 5, 2017
P2, N=104, Suspended,
Recruiting --> Active, not recruiting Initiation date: Sep 2018 --> Sep 2019 | Not yet recruiting --> Suspended | Trial primary completion date: Dec 2019 --> Dec 2020
- |||||||||| carbidopa/levodopa / Generic mfg.
Enrollment open: Dose Ranging Study of Carbidopa-levodopa (clinicaltrials.gov) - May 5, 2017
P2, N=52, Recruiting,
Initiation date: Sep 2018 --> Sep 2019 | Not yet recruiting --> Suspended | Trial primary completion date: Dec 2019 --> Dec 2020 Not yet recruiting --> Recruiting
- |||||||||| carbidopa/levodopa / Generic mfg.
Enrollment open: Carbidopa-levodopa in Neovascular AMD (clinicaltrials.gov) - May 5, 2017
P2, N=52, Recruiting,
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Trial primary completion date: Substance Abuse Pre-Treatment Screening Study (clinicaltrials.gov) - Apr 7, 2017
P=N/A, N=7500, Recruiting,
N=40 --> 0 | Recruiting --> Withdrawn Trial primary completion date: Jun 2016 --> Jun 2021
- |||||||||| carbidopa/levodopa / Generic mfg., naproxen ER / Generic mfg., naproxen / Generic mfg.
Trial primary completion date: Effect of L-dopa In Subacute Back Pain Population (clinicaltrials.gov) - Mar 17, 2017
P4, N=150, Recruiting,
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Jun 2017
|
